S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Why did Biden repeal Trump's Executive Order?! (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Why did Biden repeal Trump's Executive Order?! (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Why did Biden repeal Trump's Executive Order?! (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Why did Biden repeal Trump's Executive Order?! (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
NASDAQ:LPCN

Lipocine (LPCN) Stock Forecast, Price & News

$4.50
+0.19 (+4.41%)
(As of 06/2/2023 ET)
Compare
Today's Range
$4.33
$4.69
50-Day Range
$3.53
$5.63
52-Week Range
$3.30
$16.15
Volume
8,024 shs
Average Volume
59,077 shs
Market Capitalization
$23.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.00

Lipocine MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
1,411.1% Upside
$68.00 Price Target
Short Interest
Healthy
1.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$109,646 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.42) to ($1.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

786th out of 983 stocks

Pharmaceutical Preparations Industry

393rd out of 486 stocks


LPCN stock logo

About Lipocine (NASDAQ:LPCN) Stock

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Recap: Lipocine Q1 Earnings
Lipocine: Q1 Earnings Snapshot
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)
LPCN: 2022 Operational & Financial Update
Lipocine to Present at Biotech Showcase
See More Headlines

LPCN Price History

LPCN Company Calendar

Last Earnings
3/10/2023
Today
6/03/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPCN
Employees
13
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$68.00
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$68.00
Forecasted Upside/Downside
+1,411.1%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-10,760,000.00
Pretax Margin
-2,007.21%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$6.14 per share

Miscellaneous

Free Float
4,944,000
Market Cap
$23.40 million
Optionable
Optionable
Beta
0.95

Social Links


Key Executives

  • Mahesh V. PatelMahesh V. Patel
    President, Chief Executive Officer & Director
  • George G Nomikos
    Chief Medical Officer
  • Anthony DelConte
    Chief Medical Director
  • Nachiappan Chidambaram
    Vice President-Product Development
  • Krista Fogarty
    Chief Accounting Officer













LPCN Stock - Frequently Asked Questions

What is Lipocine's stock price forecast for 2023?

0 analysts have issued 12-month price targets for Lipocine's shares. Their LPCN share price forecasts range from $68.00 to $68.00. On average, they expect the company's stock price to reach $68.00 in the next year. This suggests a possible upside of 1,411.1% from the stock's current price.
View analysts price targets for LPCN
or view top-rated stocks among Wall Street analysts.

How have LPCN shares performed in 2023?

Lipocine's stock was trading at $6.7626 at the start of the year. Since then, LPCN stock has decreased by 33.5% and is now trading at $4.50.
View the best growth stocks for 2023 here
.

Are investors shorting Lipocine?

Lipocine saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 80,100 shares, an increase of 32.0% from the April 30th total of 60,700 shares. Based on an average trading volume of 26,100 shares, the days-to-cover ratio is currently 3.1 days. Currently, 1.6% of the shares of the company are short sold.
View Lipocine's Short Interest
.

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our LPCN earnings forecast
.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) issued its earnings results on Friday, March, 10th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

When did Lipocine's stock split?

Shares of Lipocine reverse split on the morning of Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Lipocine own?
What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Who are Lipocine's major shareholders?

Lipocine's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.66%), Wealth Effects LLC (0.85%), Two Sigma Investments LP (4.88%), Price T Rowe Associates Inc. MD (3.36%), Two Sigma Advisers LP (2.54%) and Group One Trading L.P. (0.00%). Insiders that own company stock include John W Higuchi, Krista Fogarty, Mahesh V Patel, Morgan R Brown, Richard Dana Ono and Spyros Papapetropoulos.
View institutional ownership trends
.

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $4.50.

How much money does Lipocine make?

Lipocine (NASDAQ:LPCN) has a market capitalization of $23.40 million and generates $500,000.00 in revenue each year. The specialty pharmaceutical company earns $-10,760,000.00 in net income (profit) each year or ($2.3809) on an earnings per share basis.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -